Search Results for "Allena Pharma Linkedin"
Original Source: Allena Pharmaceuticals, Inc.
Allena Pharmaceuticals, Inc. is developing and commercializing non-systemic protein therapeutics to treat metabolic and orphan diseases, with a particular focus on nephrologic and urologic conditions. The companyâs proven approach enables the design and development of oral protein therapies that remain in the gastrointestinal (GI) tract, where the protein exerts its therapeutic effect by reducing toxic metabolites without being absorbed into the b...
Matching Channels
The Datamonitor Group aims to help its clients operating in the pharmaceuticals, healthcare and biotechnology fields, offering world-leading products and services to meet the challenges of this rapi...
Labs are the hub of much of modern medicine, either in the hospital setting processing patients blood tests and other samples, in research institutions at many universities or in the headquarters of...
OxyContin, an narcotic analgesic produced by Purdue Pharma LP, nets $3m in sales annually, placing it 8th in the world for annual sales. OxyContin in the brand name for oxycodone, and is similar t...
Lyxumia® is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) for the treatment of patients with type 2 diabetes mellitus. GLP-1 is a naturally-occurring peptide hormone that is re...
Devices - medical, biotech, pharma
A medical device is a product which is used for medical purposes in patients, in diagnosis, therapy or surgery. Medical devices act by physical, mechanical, thermal, physico-chemical or chemic...
Matching News
Degrading in the gut: Sidebar: Allena Pharmaceuticals Inc. Corporate Profile
Degrading in the gut Allena Pharmaceuticals Inc. Newton, Mass. Technology: Undisclosed recombinant enzyme that degrades oxalate Disease focus: Endocrine/metabolic Clinical status: Preclinical Founded:...
Allena is developing a recombinant version of an enzyme that degrades oxalate in the GI tract to treat hyperoxaluria, a metabolic disease with renal and gastrointestinal consequences and no treatments...
Earnings Preview: LinkedIn to post 2Q results
LinkedIn is expected to quadruple its second-quarter earnings when it posts results Thursday, which would be a respite from a string of underachieving numbers from some banner names in social media s...
Want to Create Brand Loyalty? Think Beyond Multichannel Marketing and Innovate!
Précis: Multichannel marketing is one of the hottest topics in pharma marketing now... A recent LinkedIn poll from pharma d...
LinkedIn brings the biotech world down to size
The work and social platform LinkedIn operates somewhat like an ongoing life sciences industry conference, allowing investors -More-
LinkedIn: The Quiet Force Transforming Biotech & Pharma
Mark Levin’s business is biotechnology, so it’s no surprise he knew zilch about a tech company called LinkedIn as recently as two years ago. But these days Levin sounds like he can barely do his j...
Pharma 3.0 Pulls Companies into the Digital Future
Social media and mobile marketing have kick-started the pharma industry into a phase dubbed Pharma 3.0. Gone are the days of Pharma 1.0 in which companies could rely on a handful of blockbuster drug...
LinkedIn links up with panel of 'influencers'
LinkedIn is adding more expert advice to its website and making it easier for its users to find their pearls of wisdom.The online professional networking service hopes the proffered tips and advice w...
Matching PubMed Articles
iNurse: Facebook, Twitter, and LinkedIn, Oh My!
Making sense-and good use-of social media.
Structures containing the (R)-3-amino-3-methyl piperidine unit as a new pharmacophore moiety have been shown to possess moderate inhibitory activity for DPP-4 with good pharmacokinetics profile. One o...
Chirally LinkedIn: Chiral aldehydes are effective tethering catalysts for enantioselective intermolecular hydroamination, which provides access to vicinal diamine motifs in good yields and excellent e...
